Interested in unlocking the full revenue potential of your chronic pain patients while improving outcomes and reducing risk? Need an optimized Medicare strategy for chronic pain? Need help ensuring regulatory compliance?
For a limited time OPOS is offering, at no cost to you, a risk stratification analysis of your controlled substance prescribing. Using the same data the medical board and DEA have access to, with your permission, we will apply analytics to asses reasonability related to the current chronic pain treatment standard of care. The analysis will show you where your pockets of unmanaged risk are and how they deviate from the standard of care. Prescribers are often surprised to learn that some of their risk is based on what other providers, outside of the practice, may be prescribing to the patient. We will provide recommendations for managing risk and show you the untapped new revenue potential among your chronic pain patient population, including the 2023 Medicare chronic pain management services.